Heart failure plagues industrialized nations, killing more people than any other disease. It usually results from a deficiency of specialized cardiac muscle cells known as cardiomyocytes, and a robust therapy to regenerate lost myocardium could help millions of patients every year. Heart regeneration is well documented in amphibia and fish and in developing mammals. After birth, however, human heart regeneration becomes limited to very slow cardiomyocyte replacement. Several experimental strategies to remuscularize the injured heart using adult stem cells and pluripotent stem cells, cellular reprogramming and tissue engineering are in progress. Although many challenges remain, these interventions may eventually lead to better approaches to treat or prevent heart failure.
H eart regeneration has been intensely investigated, and extremely controversial, for more than 150 years 1 . In pursuit of this subject, the heart has been stabbed, snipped, contused, cauterized, coagulated, frozen, injected with toxins, infected and infarcted, in species ranging from marine invertebrates to horses 2, 3 . Why has this proven to be such a difficult challenge? The heart is one of the least regenerative organs in the body, so if there is a regenerative response, it is small in comparison to that seen in many other tissues, such as liver, skeletal muscle, lung, gut, bladder, bone or skin. For most investigators, the question is about whether there is no regeneration, which is intrinsically difficult to prove, or whether it occurs but at very low rates, which is not easy to detect but possible using highly sensitive approaches. This is more than an academic argument. Heart failure is a burgeoning public health problem, and some predict that it will reach epidemic proportions as our population ages. Cardiomyocyte deficiency underlies most causes of heart failure. The human left ventricle has 2-4 billion cardiomyocytes, and a myocardial infarction can wipe out 25% of these in a few hours 4 . Disorders of cardiac overload such as hypertension or valvular heart disease kill cardiomyocytes slowly over many years 5 , and ageing is associated with the loss of ~1 g of myocardium (about 20 million cardiomyocytes) per year in the absence of specific heart disease 6 . If the human heart has even a small innate regenerative response, it may be possible to exploit this therapeutically to enhance the heart's function. This fundamental motivation has kept investigators pursuing rare events for more than a century.
Over the past 15 years, researchers have taken a more interventional approach to the injured heart, creating the field of cardiac repair. The ultimate goal of cardiac repair is to regenerate the myocardium after injury to prevent or treat heart failure. This interdisciplinary field draws from advances in areas such as stem cells, developmental biology and biomaterials in an attempt to create new myocardium that is electrically and mechanically integrated into the heart. Cardiac repair has moved rapidly from studies in experimental animals to clinical trials involving thousands of patients. In this Review, we summarize the evidence for heart regeneration in animal models and humans. We discuss the status of research using adult stem cells and pluripotent stem cells for cardiac repair in experimental animals, and explore the promises and problems of cellular reprogramming and tissue engineering. Clinical trials will be covered only briefly, owing to space limitations, so we refer interested readers to recent reviews on this topic 7, 8 .
Heart regeneration in amphibia and fish
Unlike humans, many amphibia and fish readily regenerate limbs, appendages and internal organs after injury. There is a long history of research on amphibian heart regeneration 9 ; more recently, the zebrafish has proven to be a particularly useful model, given its substantial regenerative capacity and amenability to genetic manipulation 10 . The zebrafish heart fully regenerates after the surgical amputation of the cardiac apex -an injury that corresponds to a loss of approximately 20% of the total ventricular mass 10 . In the low-pressure zebrafish heart, this large wound is effectively sealed by an initial fibrin clot, which is gradually replaced by de novo regenerated heart tissue rather than by scar tissue [10] [11] [12] [13] . Not surprisingly, this regenerative response involves a substantial amount of cardiomyocyte proliferation. Even at baseline levels, zebrafish cardiomyocytes show a much higher degree of cell-cycle activity than equivalent cells from their mammalian counterparts. A recent study showed that approximately 3% of cardiomyocytes in the compact myocardium of uninjured adult zebrafish hearts incorporate the thymidine analogue bromodeoxyuridine (BrdU) during a seven-day pulse-labelling experiment. Two weeks after amputation of the cardiac apex, the fraction of BrdU-positive cardiomyocytes had increased by tenfold, and this parameter remained as high as 20% as late as one month after injury 10 . Initial experiments suggested that undifferentiated progenitor cells were the principal source of regenerating cardiomyocytes in zebrafish 11 , but two recent genetic fate-mapping studies unambiguously demonstrated that pre-existing committed cardiomyocytes are instead the main source 12, 13 (Box 1). The two groups independently generated transgenic zebrafish in which the cardiomyocyte-specific cmlc2 (also known as myl7) promoter drives the expression of tamoxifen-inducible Cre recombinase. These animals were crossed with a reporter line, in which Cre-mediated excision of a loxP-flanked stop sequence induces constitutive expression of green fluorescent protein (GFP). In the offspring of this cross, all pre-existing cardiomyocytes and their progeny can be induced to express GFP by tamoxifen treatment. If the regenerated myocardium were derived from undifferentiated progenitor cells, the new ventricular apex should be GFP -. Instead, both groups found that the vast majority of the newly regenerated cardiomyocytes were GFP + (refs 12, 13) . Thus, heart regeneration in zebrafish is principally mediated by the proliferation of pre-existing cardiomyocytes, rather than the generation of new cardiomyocytes from stem cells.
Limited regeneration in rodent hearts
Although they lack the remarkable regenerative capacity of the zebrafish heart, postnatal mammalian hearts also undergo some degree of cardiomyocyte renewal during normal ageing and disease. Despite all the recent attention by the field, this is not a new concept. Extremely low but detectable levels of cardiomyocyte cell-cycle activity have been reported in rodent studies dating back to the 1960s 3, 14 . Capturing the rare dividing cardiomyocytes present in mammalian hearts is technically challenging, but recent work has taken advantage of the greater specificity and throughput afforded by transgenic mouse models. For example, transgenic mice were created in which the cardiomyocytespecific α-myosin heavy chain (Myh6, also known as α-MHC) promoter drives nuclear-localized expression of β-galactosidase 15 . This convenient read-out allowed researchers to screen more than 10,000 cardiomyocyte nuclei in histological sections for the incorporation of radiolabelled thymidine, and they found labelling indices of 0.0006% for adult ventricular cardiomyocytes in intact hearts and 0.0083% for cardiomyocytes in the border zone of injured hearts 14, 15 . Although such proliferative indices are small, they raise the possibility that such phenomena could be augmented therapeutically. Proof of concept for this approach has come from transgenic mice with cardiomyocyte-restricted overexpression of the cell-cycle activator cyclin D2, because these animals show reduced scar tissue and improved mechanical function after myocardial infarction 16 . Other efforts to enhance the proliferation of adult cardiomyocytes -by manipulating oncogenes or cell-cycle regulators -have proven less consistent in improving outcomes after infarction (see ref. 17 for a comprehensive review). Pharmacological enhancement of cardiomyocyte cell-cycle activity would be more practical clinically than gene therapy, and the signalling molecules periostin 18 , fibroblast growth factor-1 (ref. 19 ) and neuregulin 1 (NRG1) 20 have all been reported to act as mitogens for adult ventricular cardiomyocytes and to exert beneficial effects on Genetic fate mapping has proven to be an invaluable tool for dissecting the mechanisms of endogenous cardiac repair in model organisms, and several laboratories have used an elegant strategy based on the conditional Cre-loxP system, which allows both temporal and cell-typespecific control of reporter expression.
After amputation, the apex of the zebrafish heart can fully regenerate. To determine the source of the newly proliferating cardiomyocytes that underlies this regeneration, a zebrafish strain carrying two transgenes was created (see Figure, a) . In one transgene, the cardiomyocyte-specific cmlc2 promoter drives the expression of tamoxifen-inducible Cre recombinase. In the second transgene, the constitutive β-actin promoter initially drives expression of the red fluorescent DsRed protein. . Instead, after amputation of the apex, the new apical myocardium was 100% GFP + , indicating that heart regeneration in the zebrafish results from the expansion of pre-existing cardiomyocytes, not from the recruitment of cardiomyogenic precursors. Another independent group reached the same conclusions using a similar experimental design 13 . An analogous genetic fate-mapping approach was used to investigate the mechanisms of cardiac regeneration in mammalian hearts 22 . Here, a double-transgenic mouse was generated in which the cardiomyocyte-specific Myh6 promoter drives tamoxifen-inducible Cre recombinase, and Cre-mediated excision of loxP-flanked stop sequences induces a switch from constitutive β-galactosidase (β-gal) to constitutive GFP expression (see Figure, b 21 .) A recent study of the mitogenic effects of NRG1 showed that simple systemic injection of this growth factor into adult mice enhanced infarct scar shrinkage and improved mechanical function 20 . The effects of NRG1 on the cell cycle were dependent on the expression of its tyrosine kinase receptor, ERBB4, by cardiomyocytes and seem to stimulate mononucleated, but not binucleated, cardiomyocytes to divide. Although this intriguing result awaits independent confirmation, it suggests a straightforward approach to enhancing ventricular repair through the administration of recombinant growth factors.
Most of the above studies focused on the proliferation of existing cardiomyocytes, and were not designed to detect cardiomyocytes formed from progenitor cells. To determine whether such progenitor cells contribute to cardiomyocyte renewal, researchers have performed an elegant genetic fate-mapping experiment in transgenic mice 22 , akin to those previously described in the zebrafish model, in which cardiomyocytes were indelibly labelled after a tamoxifen pulse (Box 1). This system allowed the authors to distinguish between cardiomyocyte renewal from pre-existing (and therefore fluorescently labelled) cardiomyocytes and cardiomyocyte renewal from unlabelled progenitor cells. Interestingly, they found no significant contribution by such progenitor cells during normal ageing, up to one year after tamoxifen treatment. However, they observed a reduction in the fraction of labelled cardiomyocytes after infarction, indicating dilution by unlabelled progenitor cells. When combined with the findings that the rate of cardiomyocyte proliferation is very low in both normal and injured rodent hearts, these data indicate that the limited endogenous reparative mechanisms in the adult mammalian heart operate differently from those in zebrafish, and depend more on replenishment by cardiomyogenic progenitor cells than on replacement by cardiomyocyte proliferation.
A recent report suggests that these differences between mammalian and fish hearts do not necessarily apply earlier in development 23 . Borrowing approaches from the zebrafish model, the authors resected the left ventricular apex of one-day-old neonatal mice and observed a brisk regenerative response reminiscent of that in the adult zebrafish. By three weeks after injury, the defect had been replaced by normal myocardial tissue, which showed normal contractile function by eight weeks. Genetic fate-mapping studies indicated that this regeneration was mediated by the proliferation of pre-existing cardiomyocytes, again as in the zebrafish. Notably, this regenerative capacity was not observed in seven-day-old mice, suggesting that its loss may coincide with cardiomyocyte binucleation and reduced cell-cycle activity. Nonetheless, in addition to representing a surgical tour de force, this study indicates that zebrafish-like regenerative mechanisms are latent in mammalian hearts. It also provides a genetically tractable model for dissecting the blocks to these mechanisms in the mammalian adult.
The evidence for human heart regeneration
Before addressing whether new cardiomyocytes are generated in the human heart after injury, it is instructive to review a few points about normal cardiac growth and adaptation to workloads (Box 2). In brief, most human cardiomyocyte nuclei are polyploid by the onset of puberty 24 . In response to pathological workloads, such as hypertension, valvular disease and post-infarction overload, human cardiomyocytes commonly reinitiate DNA synthesis without nuclear division 24, 25 . This increases cardiomyocyte nuclear ploidy further, reaching levels as high as 64n (in which n represents the haploid set). Unlike rodent cardiomyocytes 26 , most human cardiomyocytes seem to remain mononucleated throughout life 27 . Thus, DNA synthesis is common in the adult human heart, but this cannot be equated to cardiomyocyte proliferation without accounting for the process of polyploidization.
Historically, regenerative responses have been detected by either the macroscopic regrowth of the tissue or the microscopic presence of mitosis. Macroscopic regeneration of the human heart clearly does not occur. Mitosis occupies only ~2% of the cell cycle, making it hard to quantify meaningfully. Experiments have confirmed this, with some investigators reporting no mitosis after injury, and others reporting rare (and potentially abnormal) mitotic figures around the injured site [28] [29] [30] . One factor contributing to these discrepancies has been the inherent difficulty in recognizing cardiomyocyte nuclei in conventional histological sections 14 . Many of the published images are persuasive for cardiomyocyte mitosis and provide important evidence that this can occur in humans. However, extrapolation to organ turnover rates from such low numbers is perilous.
Several investigators have taken the approach of counting the number of cardiomyocytes in the human heart during normal and pathological growth 24, 25, 31, 32 , but this method is surprisingly difficult and requires many assumptions. Using a combination of meticulous dissection, histopathology, biochemical measurements of tissue DNA content and fluorescent analysis of individual nuclear DNA content, researchers have shown that from myocardial weights of 50-350 g, the cardiomyocyte nuclear number is steady at ~2 billion. Beyond that, there is a linear increase in nuclear number with increasing heart weight, reaching 4 billion cardiomyocyte nuclei in hypertrophied hearts weighing 700-900 g. The number of non-cardiomyocytes such as fibroblasts and vascular cells increases linearly with heart weight throughout life. If correct, these data indicate that cardiomyocyte renewal occurs during pathological hypertrophy. An important caveat is that the assignment of cardiomyocyte versus non-cardiomyocyte nuclear identity was based on the size and morphology of isolated nuclei. Because we know that postnatal growth and pathological hypertrophy are accompanied by increases in nuclear ploidy (and hence in size), it is possible that diploid cardiomyocyte nuclei in smaller hearts were mistakenly classified as non-cardiomyocyte nuclei. Increases in cardiomyocyte nuclear number in pathological hypertrophy have also been reported 33 , using histological sections in which the cardiomyocyte nuclei can be more readily identified.
Two studies have attempted to use more direct means to measure the rates of cardiomyocyte DNA synthesis in human hearts. The first approach, by Bergmann et al. 34 , was based on the worldwide pulse of 14 C that occurred during the atmospheric testing of nuclear weapons in the cold war. The atmospheric 14 C became incorporated into plants and entered the human food chain, labelling the DNA of dividing cells. After the Limited Nuclear Test Ban Treaty of 1963, atmospheric 14 C levels dropped rapidly. This provided researchers with pulse-chase conditions that can be used to date cells, simply by identifying when atmospheric 14 C levels match those of the DNA. As expected, non-cardiomyocytes in the normal human heart were found to be substantially younger than the patient, with ~18% turnover per year and a mean age of only four years. Notably, DNA from isolated cardiomyocyte nuclei (sorted by nuclear troponin staining) was also younger than the patient, although not nearly as young as that from non-cardiomyocytes. As indicated earlier, before one can infer cell division, it is essential to rule out a contribution from polyploidization. To do this, the authors sorted cardiomyocyte nuclei by DNA content, and analysed only the diploid DNA subset. The diploid cardiomyocyte nuclei were also younger than the patient, providing good evidence for cardiomyocyte division. Mathematical modelling suggested that cardiomyocyte renewal was age-dependent, with ~1% of cardiomyocytes being renewed per year at age 20, and 0.4% at age 75. On the basis of these kinetics, ~45% of cardiomyocytes would be predicted to be renewed over a normal human lifespan, whereas 55% would be cells persisting since birth.
In the second approach, by Kajstura et al. 35 , the rates of cardiac DNA synthesis were obtained by examining post-mortem hearts from patients with cancer that had been treated with the thymidine analogue iododeoxyuridine (IdU). This agent is incorporated into nascent DNA, where it sensitizes cells to radiation therapy. IdU was given as bolus injections or multiweek infusions, and the time between treatment and death ranged from 7 days to 4.3 years. Using immunohistochemistry to detect the IdU signal and identify cardiomyocytes, the researchers found remarkably high rates of cardiomyocyte DNA labelling, ranging from 2.5% to 46%. No IdU staining was found in control hearts from patients without cancer who had not been exposed to the radiosensitizer. Mathematical modelling suggested that cardiomyocytes turn over at a rate of 22% per year, compared with 20% for fibroblasts and 13% for endothelial cells. Furthermore, 83% of the cardiomyocyte nuclei were reported to be diploid, suggesting that this turnover reflects cell division, not increased nuclear ploidy.
It is hard to reconcile these two studies, which differ by nearly 50-fold in their estimates of cardiomyocyte turnover. An important difference seems to be related to the higher rates of cardiomyocyte DNA synthesis activity in IdU-treated patients with cancer. Kajstura et al. 35 reported threefold lower DNA synthesis rates (based on immunolabelling of the cell proliferation marker Ki-67) in control hearts from patients without cancer than in hearts from IdU-treated patients with cancer. Neither study adequately rules out a contribution from DNA repair, which can masquerade as DNA replication in these assays. This is of particular concern in patients with cancer receiving radiation treatment plus a radiosensitizer. Kajstura et al. suggested that only senescent cardiomyocyte nuclei contain troponin, which could bias the turnover studies of Bergmann and his colleagues 34 towards low proliferation. However, a follow-up paper by Bergmann et al. 36 provided evidence that nearly all cardiomyocyte nuclei were identified by troponin Fetal hearts in humans and rodents grow through the proliferation of mononucleated cardiomyocytes with diploid nuclei. In the first few days after birth, rodent cardiomyocytes withdraw from the cell cycle. By contrast, human cardiomyocytes seem to proliferate for the first few months after birth, after which replication slows markedly. The cells of both rodents and humans then undergo a period of physiological growth, increasing in size by 30-40-fold. Although most cardiomyocytes cannot grow this much with a single diploid genome, different species have taken varying approaches to solve this problem. Nearly all rodent cardiomyocytes undergo a final round of DNA replication followed by nuclear division without cytokinesis, resulting in a heart with more than 75% binucleated cells with a normal diploid (2n) content of DNA in each nucleus (see Figure, a) 
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. In humans and other primates, most cardiomyocytes undergo a final round of DNA replication, without nuclear division or cytokinesis, resulting in mononucleated cells 27 with tetraploid (4n) or higher DNA content (a) 31 . (Estimates of human cardiomyocyte binucleation rates range from 25% in enzymatically dispersed fresh tissue 27 to more than 60% in potassium-hydroxide-digested formaldehyde-fixed tissue 99 . We favour the 25% value, because the harsh potassium hydroxide digestion may selectively eliminate smaller mononucleated cardiomyocytes.) Notably, pacemaker cells of the sinoatrial and atrioventricular nodes remain small and diploid throughout life 100 . As the myocardial mass of the human heart increases, the percentage of diploid cardiomyocyte nuclei decreases steadily. This has been demonstrated by cytofluorometric analysis of human cardiomyocyte nuclear DNA content as a function of myocardial weight, after carefully removing valves, vessels and fat (see Figure, b ). (Hearts were grouped by weight into four bins for clarity.) Studies of paediatric human hearts indicate that polyploidization occurs in the pre-adolescent growth phase, from 8 to 12 years of age. Tetraploid nuclei (4n) are most common in the adult heart. During cardiac hypertrophy, octaploid nuclei (8n) become most common, with a substantial number of 16n nuclei or those with higher polyploidy. These data demonstrate that human cardiomyocytes have a substantial capacity for DNA replication.
Morphometric analysis has shown that the normal human adult number of 2 billion cardiomyocyte nuclei is reached by about 2 months of age. During physiological hypertrophy, the cardiomyocyte nuclear number remains steady. However, when the heart weight exceeds approximately 450 g (myocardial weight roughly 210 g), there seems to be a linear increase in cardiomyocyte nuclear number with increasing cardiac mass (see Figure, c ). Because human hearts do not change nuclear number with hypertrophy, this is evidence for the generation of new cardiomyocytes, either from pre-existing cardiomyocytes or from stem cells. Non-cardiomyocyte nuclei increase linearly with increasing myocardial mass (see Figure, staining. Furthermore, the findings of Kajstura et al. contradict two well-accepted principles. First, the findings suggest that more than 80% of cardiomyocyte nuclei are diploid, in contrast to most other reports that suggest they are polyploid. If the nuclei were in fact polyploid, then polyploidization could underlie the authors' high estimates of DNA synthesis. Second, the authors conclude that cardiomyocytes are as proliferative as non-cardiomyocytes, whereas most other investigators find greater orders of magnitude of proliferation in non-cardiomyocytes. Indeed, the cardiomyocyte IdU-incorporation rate (2.5-46%) detected by Kajstura et al. 35 approaches the rate reported previously for sarcomas targeted by IdU (50-70%) 37 . The heart does not proliferate like a sarcoma, so these cardiac IdU-incorporation estimates must be too high.
Taken together, these human studies provide strong evidence for plasticity in the adult human heart. There is extensive morphometric evidence for DNA synthesis and an increase in cardiomyocyte number in diseased human hearts. Cardiomyocyte division or generation from progenitor cells probably occurs in the human heart, but it seems to be a very slow process. We need better tools to study this process quantitatively, and better ways to model it, if we hope to exploit it therapeutically.
Stem cells and cell therapy
Stem-cell biology is one of the fastest moving areas of biomedical research, and among all of the solid organs, the heart has one of the most active regeneration research programmes. The field can be conceptually organized into work involving endogenous and exogenous cells. The many exogenous cell types can be further divided into pluripotent cells (such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)) and adult cells of more limited potential (such as circulating progenitor cells, resident cardiac progenitor cells and cells native to other tissues). Here we focus on the cells closest to clinical trials and those for which there are the most reliable data.
Cardiac progenitor cells
Several investigators have reported resident populations of cardiac progenitor cells (CPCs) in postnatal hearts. These were identified using a variety of approaches, including studying the expression of surface markers such as c-KIT or SCA-1 (also known as LY6A; note that SCA-1 has no apparent human orthologue) and physiological properties such as the ability to efflux fluorescent dye or form multicellular spheroids (reviewed in refs 38 and 39). Initially, it seemed that there was little overlap among CPCs identified by the different methods, and some scientists suggested that several populations of CPC exist. More recent studies indicate shared markers among once-distinct populations or different stages of maturation in the same line of cells 40, 41 , so the field may be converging.
CPCs expressing the tyrosine kinase receptor c-KIT are the most extensively studied. In the human adult, c-KIT is expressed by telocytes (formerly known as the interstitial cells of Cajal), the thymic epithelium and mature circulating cells such as haematopoietic stem cells and mast cells. Immature endothelial cells and cardiomyocytes also express c-KIT during development 42 . Small round cells expressing c-KIT have been identified in the perivascular compartment of the adult heart, and their abundance increases in human heart failure 43 . After isolation from rat and human hearts, c-KIT + cells have been reported to give rise to cardiomyocytes, smooth muscle cells and endothelial cells. Some studies indicate that, when transplanted, c-KIT + cells induce large-scale regeneration of myocardial infarcts and contribute to the formation of new myocardium and vessels 44 , whereas others suggest smallerscale regeneration 45 . On the basis of these data, a clinical trial is under way, testing the safety and feasibility of autologous c-KIT + cells as an adjunctive treatment for patients undergoing coronary bypass surgery (ClinicalTrials.gov identifier NCT00474461).
Not all studies with c-KIT + CPCs gave robustly positive results. In studies with genetic read-outs for lineage tracing and differentiation state, c-KIT + cells from the adult mouse heart have not been shown to differentiate into cardiomyocytes in vitro or after transplantation into infarcted hearts 46 . Another study using transgenic reporter mice found no evidence to suggest that endogenous c-KIT + cells differentiate into cardiomyocytes, although re-expression of c-KIT in pre-existing cardiomyocytes was identified after injury 42 . Others point out that myocardium, like all solid tissues, contains mast cells. Mast cells are small round cells that reside in clusters in the perivascular space, strongly express c-KIT and increase in number in failing hearts 47 . Studies in humans suggest that 90-100% of all of the cardiac c-KIT + cells are actually mast cells. However, expansion in culture seems to select for c-KIT + cells that lack mast-cell markers, indicating that freshly isolated cells and cultured cells are different populations 48 . Another CPC population in clinical trials is cardiosphere-forming cells. These cells are isolated on the basis of their ability to migrate out of cultured cardiac tissue fragments and form spheroids in suspension cultures 49, 50 . As one might predict, this yields a mixture of cells, some of which express stem-cell markers such as c-KIT, and others that seem to come from the stromal-vascular compartment. CPCs have been reported to give rise to cardiomyocytes in vitro and in vivo after transplantation, and to enhance cardiac function after infarction 50 . On the basis of these data, a clinical trial of autologous CPCs has been initiated for patients with recent myocardial infarctions (NCT00893360). The 'stemness' of CPCs has recently been questioned, and it has been suggested that these cells are principally cardiac fibroblasts and that CPC-derived cardiomyocytes are contaminants derived from the original tissue 51 . Thus, although the study of CPCs is an exciting, new area of cardiac research, it is also one of the most controversial. Most of the work has focused on cell culture and transplantation, driven by the clinical need for cardiac repair. We know almost nothing about the endogenous behaviour of CPCs, however. An important question remains about the role of these cells in development, homeostasis, ageing and reaction to injury. The field needs models that permit unambiguous tracing of CPC lineage and phenotype without resorting to transplantation or cell culture (Box 1).
Bone marrow cells
Considerable interest in bone-marrow-derived cells for cardiac repair was prompted by reports of haematopoietic stem cells transdifferentiating into cardiomyocytes 52 . Subsequent studies have shown that haematopoietic stem cells do not form cardiomyocytes but instead become mature blood cells after transplantation 53, 54 . Nevertheless, animal studies show improvements in ventricular function when haematopoietic cells are administered after infarction, implicating paracrine signalling as the major mechanism of action.
Work with marrow-derived stromal cells (MSCs) has followed a similar trajectory. MSCs were originally reported to transdifferentiate into cardiomyocytes 55 but are now thought to exert their main actions in a paracrine manner through the release of cytokines 56 . Interestingly, most MSCs die within days or weeks of transplantation into infarcts, yet their beneficial effects can be seen long term, suggesting a critical window of time for the action of MSCs after infarction. MSCs probably operate by many mechanisms, but considerable evidence points towards regulation of the WNT pathway. MSCs secrete antagonists of canonical WNT ligands, such as secreted frizzled related protein 2 (ref. 56) . Blocking the production of WNT antagonists limits the beneficial effects of mouse MSCs. A recent report has shown that the administration of MSCs to pig infarcts stimulated endogenous CPCs to contribute to the repair of the infarcts 57 . Further identification of paracrine mediators may allow the development of simpler, cell-free treatments based on proteins or small molecules.
Clinical trials have mostly focused on the delivery of bone marrow mononuclear cells by the coronary circulation. It should be emphasized that >99.9% of bone marrow mononuclear cells are not stem cells, but are committed, although immature, granulocytes or other haematopoietic lineages. These trials indicate that the delivery of bone marrow
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derivatives through the coronaries is feasible and safe, but the benefits are modest. MSCs are also in clinical trials (NCT00587990). There are few published results with these cells, but one of the strongest cardiacrepair treatment effects seen so far (a 14% improvement in ejection fraction -the fraction of blood ejected from the left ventricle during one contraction) was reported after the intracoronary administration of large numbers of autologous MSCs 58 . Allogeneic MSCs administered to patients intravenously within ten days of infarction were well tolerated and were associated with decreased arrhythmias and an improvement in some indices of contractile function 59 . Taken together, the best current evidence indicates that bone marrow cells do not work by directly differentiating into new cardiomyocytes. Instead, the cells have been shown to elaborate signals that control the response of cells native to the myocardium, and thereby regulate healing. Although many view this as a novel aspect of stem-cell biology, students of pathology will recognize that this phenomenon fits under a more familiar heading: inflammation. We find it useful to consider the participation of marrow derivatives in cardiac repair as part of the inflammatory response, which is known to regulate angiogenesis, cardiomyocyte survival and left ventricular remodelling after infarction.
Pluripotent stem cells
Many types of adult stem cell are unable to generate large numbers of unambiguous cardiomyocytes. This limitation does not apply to ESCs or their more recently developed 'man-made' counterpart, iPSCs. Because both ESCs and iPSCs can be propagated indefinitely, while still retaining the capacity to differentiate into almost all cell types, they are a potentially inexhaustible supply of human cardiomyocytes. Our current thinking about how cardiomyocytes arise from ESCs is shown in Fig. 1 . Human ESC-derived cardiomyocytes express early cardiac transcription factors such as NKX2.5, as well as the expected sarcomeric proteins, ion channels, connexins and calcium-handling proteins (Fig. 2) . They show similar functional properties to those reported for cardiomyocytes in the developing heart, and undergo comparable mechanisms of excitation-contraction coupling and neurohormonal signalling [60] [61] [62] [63] . Although human ESC-derived cardiomyocytes have been more intensively studied, data indicate that human iPSC-derived cardiomyocytes have a very similar phenotype 64, 65 . Importantly, cardiomyocytes from either pluripotent stem-cell type are immature and so lack the expression profile, morphology and function of adult ventricular cardiomyocytes.
The cardiac potential of ESCs and iPSCs is indisputable, but their unique origin and pluripotency presents a new set of challenges. ESCs are derived from the inner cell mass of preimplantation-stage blastocysts 66 , and this contributes to the ethical controversy surrounding their use. Moreover, ESC-based therapies will be allogeneic and require immunosuppression. iPSCs were originally generated by the reprogramming of adult somatic cells such as dermal fibroblasts by the forced expression of up to four stem-cell-related transcription factors [67] [68] [69] . As such, their derivation does not involve the destruction of embryos, and they could be used in autologous cell therapies. Nonetheless, first-generation iPSCs were problematic because the reprogramming factors were introduced using integrating viruses, raising concerns about neoplastic transformation. More recently, there have been a variety of refinements to iPSC generation that should reduce or eliminate this risk, including the use of episomal gene delivery, excisable transgenes, cell-permeable recombinant proteins and synthetic messenger RNA (see ref. 70 and references therein). Perhaps most notably, several small molecules have been shown to greatly enhance the efficiency of reprogramming 71 , inviting speculation that iPSCs may be generated using such factors alone in the near future. Further work will be required to more precisely define the phenotype and maturation potential of cardiomyocytes derived from iPSCs generated by these methods.
Another concern relating to the clinical application of pluripotent stem cells is their capacity to form teratomas after transplantation 72 . To overcome this, the field needs to develop methods to enrich ESC and iPSC derivatives for cardiomyocytes or other useful cell types In either case, the specification of the cardiovascular lineages involves a transition through a sequence of increasingly restricted progenitor cells, proceeding from a pluripotent state to mesoderm and then to cells committed to cardiovascular fates. Growth factors that regulate fate choices are listed at branch points (blue), and key transcription factors and surface markers for each cell state are listed under the cell types (green). The growth factors are useful for directing the differentiation of ESCs, whereas the markers are useful for purifying cells at defined developmental states. Primitive cardiomyocytes in the embryonic heart tube and nodal or pacemaker cells show slow electrical propagation and a small cell size. By contrast, the eventual specification of working atrial and ventricular cardiomyocytes is accompanied by more rapid conduction, ion-channel remodelling and increased cell size. Although the field has made considerable progress towards determining the early events of cardiogenesis, a better understanding of how pacemaker and chamber-specific cardiac subtypes are formed is required for clinical applications. BMPs, bone morphogenetic proteins; CNTN2, contactin-2; CX, connexin; FOXA2, forkhead box protein A2; HCN4, potassium/ sodium hyperpolarization-activated cyclic nucleotide-gated channel 4; MESP, mesoderm posterior protein; MLC2a/v, myosin light chain 2a and/ or 2v; MYH, myosin heavy chain; NPPA, natriuretic peptide precursor A; NRG1, neuregulin 1; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; SCN5A, sodium channel protein type 5 subunit α; SOX, SRY-related high-mobility-group box; TBX, T-box transcription factor; VEGF, vascular endothelial growth factor; VEGFR-2, VEGF receptor-2.
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(such as endothelial, smooth muscle and stromal cells). Historically, ESCs have been differentiated by culture in three-dimensional aggregates known as embryoid bodies, in medium containing a high percentage of fetal calf serum. This method is poorly cardiogenic, and differentiated human embryoid bodies are typically composed of less than 1% cardiomyocytes 73 . More recently, our group and others have used insights from developmental biology to devise better controlled approaches in which human ESCs and iPSCs are treated with defined factors, resulting in highly enriched populations of cardiomyocytes [74] [75] [76] . A common theme with such methods has been the manipulation of cardioinductive molecules belonging to the transforming growth factor-β superfamily -specifically, activin and the bone morphogenetic proteins (BMPs). Our group has reported a protocol involving the serial application of activin A and BMP4, for example, which reliably yields ~60-80% human ESC-derived cardiomyocytes in large-scale preparations (~10 8 -10 9 total cells) 74, 77 . Further refinements are possible by manipulating the WNT-β-catenin signalling pathway 78 , which mediates biphasic effects on ESC cardiogenesis, promoting mesodermal induction early but inhibiting cardiogenesis late 79 75 . If such cells could be induced to selfrenew, they would potentially be very useful for cardiac repair.
Human ESC-derived cardiomyocytes have been shown to engraft in infarcted mouse, rat, guinea pig and pig hearts (Fig. 3) , forming islands of nascent, proliferating human myocardium within the scar zone 74, 84, 85 . This partial remuscularization was accompanied by beneficial effects on regional and global cardiac function 74, 84 , although some investigators have questioned whether these effects are sustained at later time points 86 . Notably, the mechanism (or mechanisms) underlying the observed improvements in contractile function remains unresolved. In the aforementioned rodent studies, most of the graft tissue was isolated from the host myocardium by means of scar tissue, which may prevent synchronous beating. Furthermore, these human cells, which fire in vitro at ~50-150 beats per minute (b.p.m.) 77 , may not keep pace with the rapid rate of rats (~400 b.p.m.) and mice (~600 b.p.m.). If they cannot, then the observed salutary effects probably resulted from an indirect, paracrine mechanism, like those described above for adult cells. This also indicates that further beneficial effects on cardiac function may be possible after transplantation to a slower-rated recipient, such as a canine or porcine infarct model.
Reprogramming fibroblasts to cardiomyocytes
Fifteen years ago, researchers showed that fibroblasts could be transdifferentiated into skeletal muscle in vitro or in the injured heart by overexpressing the gene encoding the myogenic transcription factor, MyoD 87 . Despite an intensive search by several groups, no comparable master gene for cardiac muscle was found, and interest in reprogramming waned. Spurred by the discovery of iPSCs, scientists have returned to this field, using combinations of transcription factors to reactivate core transcriptional networks of desired cell types. In an attempt to induce cardiac differentiation, researchers performed a systematic screen of 14 cardiac transcription factors for their ability to activate a cardiac-specific transgene -the Myh6 promoter driving yellow fluorescent protein (YFP) expression -in cardiac fibroblasts 88 .
The full cocktail activated fluorescence in ~1% of cells. A systematic winnowing yielded three transcription factors (MEF2C, GATA4 and TBX5) that activated the transgene in 20% of fibroblasts. About 4% of the cells expressed endogenous sarcomeric proteins such as cardiac troponin T, and only ~1% showed functional properties such as spontaneous beating. Thus, most of the YFP + cells were only partially reprogrammed, although their global gene expression patterns had shifted markedly from fibroblast to cardiomyocyte.
While this manuscript was under review, a different method of reprogramming mouse embryonic fibroblasts to cardiomyocytes was reported 89 . This group used the 'Yamanaka factors' -OCT4 (also known as POU5F1), SOX2, KLF4 and c-MYC -to initiate reprogramming, but they blocked signalling through the JAK-STAT pathway, which is required for pluripotency in the mouse, and added the cardiogenic factor BMP4. These modifications yielded minimal generation of iPSCs, but instead activated the cardiac progenitor program and, within 2 weeks, generated substantial numbers of beating colonies. By 18 days after induction, approximately 40% of the cells expressed cardiac troponin T. The authors attributed the increased efficiency to the generation of highly proliferative progenitor cells, as opposed to the formation of cardiomyocytes with low proliferative potential. It should also be noted that this study used mouse embryonic fibroblasts, whereas the systematic screen of 14 transcription factors was principally in postnatal mouse cardiac fibroblasts.
Reprogramming the scar-forming fibroblast to a cardiomyocyte is intuitively appealing, particularly if it can be done directly in the infarct. To succeed clinically, we need to know how normal these reprogrammed cardiomyocytes are, and the process will have to be much more efficient and transgene-free. Despite some challenges, this is an exciting avenue of research and could be a game changer.
Tissue engineering
Tissue engineering refers to the growth of three-dimensional tissues in vitro, with the aim of building more biologically relevant models for in vitro study or tissues for in vivo regenerative therapy. Most commonly, this involves the use of porous, biodegradable scaffolds onto which cells are seeded, but other approaches include casting cells into hydrogels or creating scaffold-free tissues composed only of cells and the matrix they secrete. Synthetic materials have big advantages in manufacturability, typically being easy, cheap and reproducible to make. However, synthetics generally have worse biocompatibility, because they cause foreign-body inflammatory reactions and, sometimes, release locally toxic degradation products. Bioreactors are often used in tissue engineering to provide electrical and mechanical conditioning or to deliver nutrients to the tissue by perfusion systems.
A major aim of bioengineering is to improve the host response to biomaterials, in essence, to make materials that can heal 90 . Surprisingly, the chemical composition of a material does not have a major influence on how the body responds to it. Whether materials are organic or metallic, hydrophobic or hydrophilic, or positively or negatively charged, they all cause similar foreign-body reactions. Instead, what the body seems to sense is the surface topography of a material 90 . When surfaces are smooth, there is intense inflammation and scarring, creating a fibrotic capsule around the implant. If a surface is given a more complex topography, for example, by creating pores or grooves, there is less inflammation, scarring diminishes and blood vessels grow into the implant. Systematic variation in the topology can 'tune' this host response. For example, our tissueengineering group has developed scaffolds with two compartments: cylindrical channels to generate cables of cardiomyocytes, surrounded by a network of smaller interconnected pores for stromal and vascular ingrowth 91 . The pores are optimally sized to maximize vascularization within the implant and minimize fibrosis around it.
The cardiomyocytes used in tissue engineering have been immature cells derived from young animals or stem cells. To take on an adult workload, these cells will need to organize into the cable-like structure of myocardium and increase their size by more than 20-fold compared with the neonatal stage. There is a continuing debate in tissue engineering about whether this maturation should take place before or after transplantation. On the one hand, electrical 92 and mechanical 93 stimulation in vitro enhance hypertrophy, alignment and electromechanical function of rat cardiomyocyte constructs. On the other hand, greater cell differentiation is associated with worse survival after transplantation 94 , so there is probably a point of diminishing returns. This needs to be explored further experimentally.
One of the big lessons from tissue engineering has come from studies comparing cardiomyocyte-only with mixed-cell constructs. When cardiomyocyte-only constructs are transplanted, the tissue survives poorly. When vascular endothelial cells together with a stromal cell population are included, the endothelial cells form networks resembling a primitive vascular plexus, and the stromal cells form a provisional matrix that enhances mechanical integrity 95, 96 . After transplantation, the endothelial network organizes into a definitive vascular network that connects to the host circulation, bringing blood flow into the tissue several days sooner than would otherwise be seen. Indeed, our group and others have demonstrated improved survival of prevascularized human myocardial constructs incorporating vascular and stromal elements compared with constructs containing cardiomyocytes alone 95, 97 . This indicates that there is considerable synergy to including vessels and connective tissue elements when engineering tissue.
Tissue engineering has not been as extensively studied as cell transplantation in preclinical disease models, but initial studies are promising. A recent study 93 prepared constructs of engineered rat heart tissue from neonatal cardiomyocytes and conditioned them for several days using a cyclic stretch system. The constructs were sutured to the surface of rat hearts that had been infarcted two weeks previously, and were studied one month after implantation. Compared with infarcted hearts receiving non-contractile constructs, hearts receiving the engineered heart tissue had better contractile function, and interestingly, conduction velocities across the infarct were improved, probably because the grafts had electrically connected to the surrounding viable myocardium. Another group reported that patches generated from cardiosphere-derived CPCs can enhance heart function after infarction 98 , and there are hints that tissue engineering also provides a larger graft size compared with cell transplantation.
Perspective
After more than a decade of furious activity, the science of stem cells seems to be catching up with its promise. Clinical-scale preparations of the main cardiac cell types can now be generated, and we are learning the rules for building myocardium and keeping it alive after transplantation. Clinical trials have established techniques for cell delivery, and protocols for establishing feasibility, safety and early-stage efficacy in humans are in place. The first patient trials have demonstrated safety with hints of efficacy. So far, so good.
That said, many short-and long-term challenges remain. In the near term, it will be important to derive the right subtype of cardiomyocyte, for example, ventricular cardiomyocytes that are free of pacemaker cells for repair of an infarct. The major challenge facing the field of adult CPCs is to develop protocols with higher yields of definitive cardiomyocytes. Researchers studying pluripotent stem cells need to identify the optimal stage of differentiation and demonstrate that these cells can be used without tumorigenesis. The question of allogeneic versus autologous cells remains open. Although desirable, autologous cells will be more expensive, more variable, and the time needed to expand them precludes their use in any acute setting. Allogeneic cells will provide the only off-the-shelf product, but we need to learn how best to manage the immune response to prevent their rejection. All of these efforts will be advanced by improvements in integration of the graft, including control of vascularization (growth of both arterial conduits and microvasculature), inflammation and scarring. Further ahead, in situ manipulation of cells in the heart may allow us to control their fates, thereby obviating transplantation. For example, it may be possible to control CPCs using small molecules or growth factors to enhance their regenerative abilities. Fibroblasts in infarcts could potentially be reprogrammed directly to cardiomyocytes. Given our increasing ability to control the fates of cells and tissues, the debate over whether the heart is intrinsically terminally differentiated seems anachronistic, for the heart does not exist apart from the person who knows how to manipulate it. It is more useful to ask what we can do to promote cardiac regeneration best, and then do it. ■
